EFTA00304964.pdf

EARt [ Pc 09 1 LabCoro Raritan Laouorp 69 First Avenue Raritan, NJ 08869-1800 ('hone: 877-547-6837 N, „,...„ Nth ,R., l'..n: II) Connol NomIni Acoand No m n., ”I —nnsni Minn< Nund,r How 263-480-2797-0 II CNT31143092 31143092 , 212-535-1012 70 ifi lddN mw A,,,...IA.w., EPSTEIN Woodson Merrell I'.“ , r I \,n, l'ancout Allan.: JEFFREY bialvol.m. 44 E 67th St New York NY 10065 An- 01101), ItncAndth 'w ii laginr. 60/08/00 01/20/53 M I'dficni Atkin:, Additional Innitnunon 9 E 71ST ST NEW YORK NY 10065 UPIN: A62553 hate and I MC (OIICO•Ai hale I 111{10 I /AO 31111 I my '<ginned Pli).n.i.d. %auk. Nil Ps),Kisilp 09/20/13 14:00 09/21/13 09/25/13 15:06ET MERRELI. , W 1023153509 MERRELL I co. /Meted NMR LipoProfile; CBC With Differential/Platelet; Comp. Metabolic Panel 114): PE.Interp(Rfx IFE).5; Lyme Ab/Western Blot Reflex Iron and TIBC; Testosterone,Pree+weakly Bound; Prolactin; OHM-Sulfate; Homocystle)ine. Plasma; C-Reactive Protein, Cardiac: Hemoglobin Ale: Prostate-Specific Ag. Serum TSH; Vitamin D, 25-Hydroxy; Uric Acid, Serum; GOT; Insulin; Ambiguous Test Order; Ferritin, Serum Request Problem TESTS RESULT FLAG UNITS REFERENCE INTERVAL LAB NMR LipoProfile LDL Particle Number 01 LDL-P 2111 High nmol/L <1000 01 Low < 1000 Moderate 1000 - 1299 Borderline-High 1300 - 1599 High 1600 - 2000 > 2000 Very High Lipids 01 LDL-C NOTES: mg/dL <100 01 LDL-C cannot be calculated because triglycerides are > 400 mg/dL. Optimal 100 Above optimal 100 129 Borderline 130 159 High 160 189 Very high 189 HDL-C Low mg/dL >=40 01 Triglycerides High mg/dL <150 01 Cholesterol, Total High mg/dL <200 01 LDL and HDL Particles 01 HDL-P (Total) 28.7 Low umo3/L >= 30.5 01 Small LDL-P 1548 High nmol/L <= 527 01 LDL Size 19.8 Low DM > 20.5 01 *** INTERPRETATIVE INFORMATION*** PARTICLE CONCENTRATION AND SIZE <--Lower CVD Risk Higher CVD Risk--> LDL AND HDL PARTICLES Percentile in Reference Population HDL-P (total) High 75th 50th 25th Low >34.9 . 34.9 30.5 26.7 <26.7 EPSTEIN, JEFFREY 263-480-2797-0 Seq 6 5515 09/25/13 15:06 ET FINAL REPORT Page 1 of 6 This document contains plivaie and confidential health informalicn protected by state and federal law. 02004-o Laboratory Corporation of America Holdings If you have received this document in error. please call 800-631-5250 All Rights Reserved DOC I Va. 1.49 EFTA00304964  LabCorp Raritan LakCeop 69 First Avenue Raritan. NJ 08869-1800 Phone. 877-547-6837 {IAMBI Naar Specimen Mundy. EPSTEIN, JEFFREY 263-480-2797-0 .v. dtaa Smith,' I to oto ID Control Mitotic' Date and Time Collected Date Remittal SD. AttelY/WDI Date of Bull 31143092 CNT31143092 09/20/13 14:00 09/25/13 M 60/08/00 01/20/53 TESTS RESULT FLAG UNITS REFERENCE INTERVAL LAB Small LDL-P Low 25th 50th 75th High <117 117 527 839 >839 LDL Size <-Large (Pattern A)-> <-Small (Pattern B)-> 23.0 20.6 20.5 19.0 Insulin Resistance Score 01 LP-IR Score 100 High <= 45 01 LP-IR Score is inaccurate if patient is non-fasting. The LP-IR Score combines information from lipoprotein particle concentration and size to give improved assessment of insulin resistance and diabetes risk. Small LDL-P, LDL Particle Size, HDL-Particle, and LP-IR Score have been validated by LipoScience but not cleared by US FDA; the clinical utility of these test results has not been fully established. INSULIN RESISTANCE MARKER <--Insulin Sensitive Insulin Resistant--> Percentile in Reference Population Insulin Resistance Score LP-IR Score Low 25th 50th 75th High <27 27 45 63 >63 CBC With Differential/Platelet WBC 6.4 x10E3/uL 3.4 10.8 02 RBC 5.24 x10E6/uL 4.14 5.80 02 Hemoglobin 15.3 g/dL 12.6 17.7 02 Hematocrit 43.9 37.5 51.0 02 MCV 84 fL 79 97 02 MCH 29.2 pg 26.6 33.0 02 MCHC 34.9 g/dL 31.5 35.7 02 RDW 14.3 12.3 15.4 02 Platelets 269 xl0E3/uL 155 379 02 Neutrophils 56 40 74 02 Lymphs 31 14 46 02 Monocytes 8 4 12 02 Eos 4 0 5 02 Basos 1 0 3 02 Neutrophils (Absolute) 3.6 xl0E3/uL 1.4 7.0 02 Lymphs (Absolute) 2.0 x10E3/uL 0.7 3.1 02 Monocytes(Absolute) 0.5 xl0E3/uL 0.1 0.9 02 Eos (Absolute) 0.3 xl0E3/uL 0.0 0.4 02 Baso (Absolute) 0.1 xl0E3/uL 0.0 0.2 02 Immature Granulocytes 0 0 2 02 Immature Grans (Abs) 0.0 xl0E3/uL 0.0 0.1 02 EPSTEIN, JEFFREY 263-480-2797-0 Seq 65515 09/25/13 15:06 FT FINAL REPORT Page 2 of 6 This document contains private and contidential health information protected by state and federal law. 01004-13 Laboratory Corporation of Ante( Ica m Holdings If you have received dm document in mut. please call 800-631-5250 All Righu Reserved DOCI Ver. 1.49 EFTA00304965  LabCorp Raritan Loci3Com 69 First Avenue Raritan. NJ 08869-1800 Mow 877-547-6837 EPSTEIN, JEFFREY 263-480-2797-0 t‘incell) C.oll.4N.Oet I /.5Ie aml I inn' “dir. icd Rile ileilitled Sc• A.,.1 'NCI) l,,,,I lluth 31143092 CNT31143092 09/20/13 14:00 09/25/13 M 60/08/00 01/20/53 TESTS RESULT FLAG UNITS REFERENCE INTERVAL LAB Comp. Metabolic Panel (14) Glucose, Serum (1103 High) mg/dL 65 - 99 02 BUN 19 mg/dL 8 - 27 02 Creatinine, Serum 0.94 mg/dL 0.76 - 1.27 02 eGFR if NonAfricn Am 88 mL/min/1.73 >59 eGFR If Africn Am 101 mL/min/1.73 >59 BUN/Creatinine Ratio 20 10 - 22 Sodium, Serum 139 mmol/L 134 - 144 02 Potassium, Serum 4.1 mmol/L 3.5 - 5.2 02 Chloride, Serum 98 mmol/L 97 - 108 02 Carbon Dioxide, Total 19 mmol/L 19 - 28 02 Calcium, Serum 10.1 mg/dL 8.6 - 10.2 02 Protein, Total, Serum 7.3 g/dL 6.0 - 8.5 02 Albumin, Serum 4.5 g/dL 3.6 - 4.8 02 Globulin, Total 2.8 g/dL 1.5 - 4.5 A/G Ratio 1.6 1.1 - 2.5 Bilirubin, Total 0.6 mg/dL 0.0 - 1.2 02 Alkaline Phosphatase, S 58 IU/L 44 - 102 02 AST (SCOT) IU/L 0 - 40 02 ALT (SGPT) High IU/L 0 - 44 02 PE+Interp(Rfx IFE),S Albumin 4.2 g/dL 3.2 - 5.6 02 Alpha-1-Globulin 0.2 g/dL 0.1 - 0.4 02 Alpha-2-Globulin 0.8 g/dL 0.4 - 1.2 02 Beta Globulin 1.0 g/dL 0.6 - 1.3 02 Gamma Globulin 1.0 g/dL 0.5 - 1.6 02 M-Spike Not Observed g/dL Not Observed 02 Globulin, Total 3.1 g/dL 2.0 - 4.5 A/G Ratio 1.4 0.7 - 2.0 Please note: 02 Protein electrophoresis scan will follow via computer, mail, or courier delivery. Interpretation(See Below) 02 The SPE pattern appears essentially unremarkable. Evidence of monoclonal protein is not apparent. Lyme Ab/Western Blot Reflex Lyme IgG/IgM Ab 0.92 index High 0.00 - 0.90 02 Negative <0.91 Equivocal 0.91 - 1.09 Positive >1.09 Note: The CDC currently advises that Western blot testing be performed following all equivocal or positive EIA results. Final diagnosis should include appropriate clinical findings and a positive EIA which is also positive by Western blot. EPSTEIN, JEFFREY 263-480-2797-0 Seq M 5515 09/25/13 15:06 ET FINAL REPORT Page 3 of 6 This document contains private and confidential health information protected by state and federal law. 02004-13 Laboratory Corporation of America Holdings If you have received this document in crux. please call 800-631-5250 All Rights Reserved DOCI Ver. 1.49 EFTA00304966  LabCorp Raritan La kaggrp 69 First Avenue Raritan, NJ 08869-1800 Phone- 877-547-6817 Patient Name Specimen N, i h'. , EPSTEIN, JEFFREY 263-480-2797-0 %."..w...6. Pawn. In CONS Mantel Dale and Tiny Collected Daw Reported Se% ApeiSAI/Di 13,Oc , , —Hi. 31143092 CNT31143092 09/20/13 14:00 09/25/13 M 60/08/00 01/20/53 TESTS RESULT FLAG UNITS RISTERENCE INTERVAL LAD Lyme Ab Interp.,E1A Equivocal 02 Lyme Ab IgG by WB: 02 IgG P93 Ab. Absent 02 IgG P66 Ab. Absent 02 IgG P58 Ab. Present Abnormal 02 IgG P45 Ab. IgG P41 Ab. IgG P39 Ab. Absent Present Abnormal Absent 0 02 02 02 IgG P30 Ab. Absent 02 IgG P28 Ab. Absent 02 IgG P23 Ab. Absent 02 IgG P18 Ab. Absent 02 Lyme IgG WB Interp. Negative 02 Positive: 5 of the following Borrelia-specific bands: 18,23,28,30,39,41,45,58, 66, and 93. Negative: No bands or banding patterns which do not meet positive criteria. Lyme Ab IgM by WB: 02 IgM P41 Ab. Absent 02 IgM P39 Ab. Absent 02 IgM P23 Ab. Absent 02 Lyme IgM WE Interp. Negative 02 Note: An equivocal or positive EIA result followed by a negative Western Blot result is considered NEGATIVE. An equivocal or positive EIA result followed by a positive Western Blot is considered POSITIVE by the CDC. Positive: 2 of the following bands: 23,39 or 41 Negative: No bands or banding patterns which do not meet positive criteria. Criteria for positivity are those recommended by CDC/ASTPHLD. p23=Osp C, p41=flagellin Note: Sera from individuals with the following may cross react in the Lyme Western Blot assays: other spirochetal diseases (periodontal disease, leptospirosis, relapsing fever, yaws, and pinta); connective autoimmune (Rheumatoid Arthritis and Systemic Lupus Erythematosus and also individuals with Antinuclear Antibody); other infections (Rocky Mountain Spotted Fever; Epstein-Barr Virus, and Cytomegalovirus). Lyme Disease Ab, Quant, IgM <0.91 index 0.00 - 0.90 02 Negative <0.91 EPSTEIN, JEFFREY 263-480-2797-0 Seri a 5515 09/25/13 15:06 ET FINAL REPORT Page 4 of 6 This document contains private and confidential health infonnaliOn protected by state and federal law. O2004-B Laboratory Corpoi anon of America la Holdings If you have received this document in time, please call 800-631-5250 All Rights Reserved DOCI Vet. 1.49 EFTA00304967  LabCorp LabCorp Raritan 69 First Avenue Raritan, NJ 08869-1800 NwmNmw Phone. 877-547-4837 SpodinoNwOn EPSTEIN, JEFFREY 263-480-2711t0 s....mswo.1 PaOm II) Conuol Nunftf flue and Mm Reuened Sex AROYAM 4.01Mb 31143092 CNT31143092 09/20/13 14:00 09/25/13 M 60/08/00 0/53 TESTS RESULT !LILO lawn. RIMSIUDICE XliTZRVAL LAS Equivocal 0.91 - 1.09 Positive >1.09 Note: IgM levels may peak at 3-6 weeks post infection, then gradually decline. FDA currently advises that Western Blot testing be performed following all equivocal or positive EIA results. Final diagnosis should include appropriate clinical findings and a positive EIA which is also positive by Western Blot. Iron and TIBC Iron Bind.Cap.(TIBC) 329 ug/dL 250 - 450 UIBC 244 ug/dL 150 - 375 02 Iron, Serum 85 ug/dL 40 - 155 02 Iron Saturation 26 % 15 - 55 Testosterone,Free+weakly Bound Testosterone, Serum 178 Low ng/dL 348 - 1197 02 Prolactin 4.2 ng/mL 4.0 - 15.2 02 DHEA-Sulfate 207.7 ug/dL 51.7 - 295.0 02 **Please note reference interval change** Homocyst(e)ine, Plasma 12.8 umol/L 0.0 - 15.0 02 C -Reactive Protein, Cardiac 1.04 mg/L 0.00 - 3.00 02 Relative Risk for Future Cardiovascular Event Low <1.00 Average 1.00 - 3.00 High >3.00 Hemoglobin Alc High 4.8 - 5.6 02 Increased risk for diabetes: 5.7 - 6.4 Diabetes: >6.4 Glycemic control for adults with diabetes: <7.0 Prostate-Specific Ag, Serum Prostate Specific Ag, Serum 0.8 ng/mL 0.0 - 4.0 02 Roche ECLIA methodology. According to the American Urological Association, Serum PSA should decrease and remain at undetectable levels after radical prostatectomy. The AUA defines biochemical recurrence as an initial PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory PSA value 0.2 ng/mL or greater. EPSTEIN, JEFFREY 263-480-2797-0 Seq./5515 09/25/13 15:06 ET FINAL REPORT Page 5 of 6 Ibis document contains cm, ale and confidential health information protected by slate and federal law. 02004-13 Laboratory Corporation of America ® Holdings If you have recerdcd this document in cnor. please call 800-631-5250 All Rights Reserved DOCI Ver. 1.49 EFTA00304968  LabCorp Raritan 69 First Avenue Raritan. NJ 08869-1800 Phone. 877-C47-6817 NimemNanse EPSTEIN, JEFFREY 263-480-2797-0 ii, ('M 0 Mmther Mlle mildTime CWInied Dar Itelloned Se + AO YAM M IX* orMell 31143092 CNT31143092 09/20/13 14:00 09/25/13 M 60/08/00 01/20/53 TESTS RESULT nate SNITS REFERENCE INTERVAL LAB Values obtained with different assay methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease. TSH 1.680 u/U/mL 0.450 - 4.500 02 vitamin D, 25-Hydroxy 41.4 ng/mL 30.0 - 100.0 02 vitamin D deficiency has been defined by the Institute of Medicine and an Endocrine Society practice guideline as a level of serum 25-0H vitamin D less than 20 ng/mL (1,2). The Endocrine Society went on to further define vitamin D insufficiency as a level between 21 and 29 ng/mL (2). 1. ION (Institute of Medicine). 2010. Dietary reference intakes for calcium and D. Washington DC: The National Academies Press. 2. Bolick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. JCEM. 2011 Jul; 96(7):1911-30. Uric Acid, Serum Uric Acid, Serum 7.1 mg/dL 3.7 - 8.6 02 Please Note: 02 Therapeutic target for gout patients: <6.0 GGT 18 IU/L 0 - 65 02 Insulin High uIU/mL 2.6 - 24.9 02 Ambiguous Test Order 02 Attempts to contact your facility to clarify an ambiguous test order were unsuccessful. Please contact the laboratory to verify the request. Specimens are outinely held for 7 days from date of receipt. Ambiguous test order: (7 :910: ele i b itiC10 ) A 028240 Ferritin, Serum 121 ng/mL 30 - 400 02 Request Problem 03 Test Not Performed. Specimen is lipemic. TEST: 143257 Testost., % Free+Weakly Bound Panel: 143255 01 LipoScience Inc S7 Dir: Deanna Franke, PhD 2500 Sumner Blvd. Raleigh. NC 27616-3235 02 RN LabCorp Raritan Dir: Aracell B Reyes, MD 69 Pirst Avenue, Raritan. NJ 08869-1800 03 BN LabCorp Burlington Dir: William F Hancock. MD 1447 York Court, Burlington, NC 27215-3361 For inquiries, the physician may contact Branch: 800-631-5250 Lab: 877-547-6837 EPSTEIN, JEFFREY 263-480-2797-0 Seq./ 5515 09/25/13 15:06 ET FINAL REPORT Page 6 of 6 This document contains private and confidential health information protected by slate and federal law O2004. l) Laboratory Corporation of America Holdings If you have received this document in mot. please call 800-631-5250 All Rights Reserved DOCI Ver 1.49 EFTA00304969 Laboratory Corporation of America Special Chemistry Department Raritan, New Jersey Serum Protein Electrophoresis Specimen Number 263480279706 Account No./Name: 31143092-Woodson Merrell Total Protein: 7.3 DID: Patient Name: EPSTEIN,JEFFREY Account Address 1: Patient Id: Account Address 2: 44 E 67th St Birthdate: 20-JAN-1953 Account Address 3: New York, NY 10065 SPIFE SPE Split Beta Sample 9 09-23-2013 12:45:08:08 Status:0k Fraction 96 gidis g/dL Range Albumin 58.1 4.2 3.2 5.6 Alpha 1 2.7 0.2 0.1 0.4 Alpha 2 11.2 0.8 0.4 1.2 Beta 13.9 1.0 0.6 1.3 Gamma 14.1 1.0 0.5 1.6 Total 7.3 6.0 8.5 Comment The SPE pattern appears essentially unremarkable. Evidence of monoclonal protein is not apparent. EFTA00304970  LabCorp Raritan LabCorp 69 First Avenue Raritan. NJ 08869-1800 Phone: — Paiigen) °maul Hung= Ammo' Number Meagan Phone Number Row 263-480-2797-1 CNT31143092 31143092 212-535-1012 70 NimmIsmNalm MommAddism EPSTEIN Woodson Merrell I . par.cusikuvsmw JEFFREY roealsol.... 44 E 67th St New York NY 10065 Ag itemMh Imes Birth Sex Uaami, 60/08/00 01/20/53 M Patine MKS. AddahxrunOnm‘m.m 9 E 71ST ST NEW YORK NY 10065 UPIN: A62553 Dale and Time Collected I Da Ern; I Dete and nay Nrwird MI)u.i.m Nam- NM mi'mcon ID 09/20/13 14:00 09/25/13 09/26/13 09:05ET MERRELL , W 1023153509 MERRELL Is Ordered FSH and LH: Written Authorization TESTS RESULT TYLAO UNITS REFERENCE INTERVAL ran Fell and LH LH 5.3 mIU/mL 1.7 - 8.6 01 FSH 4.5 mIU/mL 1.5 - 12.4 01 Written Authorization Written Authorization Received. 01 Authorization received from SIGNATURE FILE 09-25-2013 Logged by Anca Orban 01 RN LabCorp Raritan Dir: Araceli B Reyes, ND 69 First Avenue, Raritan, NJ 08869-1800 For inquiries, the physician may contact Branch: 800-631-5250 Lab: 800-631-5250 EPSTEIN, JEFFREY 263-480-2797-1 Seq 0 5522 09/26/13 09:06 ET FINAL REPORT Page 1 of 1 This document contains private and confidential health information protected by state and federal law. WON-II Laboratory Coiporation of America 0 Holdings If you have received this document in error. please call 8 0 0-631-5250 All Rights Reserved DOCI Ver I.34 EFTA00304971  LabCorp Raritan LabCorp K NOW'. 111 69 First Avenue Raritan. N 08869-1800 Comol Nutawr Access Numtwr Phone. 800-762-4344 Account) Maw Numbs Nwic 263-480-3235-0 CMK31143092 31143092 212-535-1012 70 'siege I JA NJIAC /woman) Adds.. EPSTEIN Woodson Merrell I•i p., I...I +.:r Noes Nikklk Name JEFFREY hul V alium 44 E 67th St New York NY 10065 % I:low 60/08/00 01/20/53 M aiss &Strew AiMmogul W."mw.w 9 EAST 71ST ST NEW YORK NY 10065 UPIN: A62553 Hue awn me fit owl I Wm I meted I floe and Timc )(twee.) Mywcom) Nw w NM I lo went') M 09/20/13 14:00 09/21/13 09/26/13 09:0SET MERRELL , W 1023153509 Tor) I ktlered Lp-PLA2 TESTS RESULT FLEE UNITS RErens:ea INTERVAL LAS Lp-PLA2 137 ng/mL 131 - 199 01 Low Risk <200